Cantargia breast cancer study fully recruited - Edison

Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy, compared to chemotherapy alone, in triple negative breast cancer. The initial efficacy results are anticipated from mid-2025, potentially representing a near-term catalyst for the company.

The prior interim update from the Phase Ib dose-finding portion of the programme (n=15) were encouraging, showing an overall response rate of 60%, median progression-free survival of 6.6 months and overall survival of 12.8 months.

Länk till analysen i sin helhet: https://www.edisongroup.com/spark/cantargia-omx-canta-breast-cancer-study-fully-recruited/SE0006371126/